# Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

> **NCT03759392** · PHASE3 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 276 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Omecamtiv Mecarbil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03759392
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2021-11-08
- **Final completion:** 2022-01-06
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759392, "Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03759392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*